September 2025

Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab

Glob Health Med. 2025 Aug 31;7(4):334-339. doi: 10.35772/ghm.2025.01054. ABSTRACT Rheumatoid arthritis (RA) is a chronic inflammatory disease… Read More